Hansoh Pharmaceutical Group Company Limited

HKSE:3692.HK

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

China

Market Cap

USD 21.06 B

Share Price

USD 3.54

Avg Daily Volume

12,411,631

Change (1 day)

0.04%

Change (1 year)

66.48%

Change (YTD)

58.99%

Hansoh Pharmaceutical Group Company Limited Total Liabilities for the year ending December 31, 2024: USD 407.86 M

Hansoh Pharmaceutical Group Company Limited Total Liabilities is USD 407.86 M for the year ending December 31, 2024, a -60.03% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Hansoh Pharmaceutical Group Company Limited Total Liabilities for the year ending December 31, 2023 was USD 1.02 B, a -4.26% change year over year.
Hansoh Pharmaceutical Group Company Limited Total Liabilities for the year ending December 31, 2022 was USD 1.07 B, a -5.04% change year over year.
Hansoh Pharmaceutical Group Company Limited Total Liabilities for the year ending December 31, 2021 was USD 1.12 B, a 151.19% change year over year.
Hansoh Pharmaceutical Group Company Limited Total Liabilities for the year ending December 31, 2020 was USD 446.80 M, a -52.36% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

HKSE: 3692.HK

Hansoh Pharmaceutical Group Company Limited

CEO	Ms. Huijuan Zhong
IPO Date	June 14, 2019
Location	China
Headquarters	No.45 Huanghe Road
Employees	8,989
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.